Seegene Inc
상단으로
Contact Us

  • Real-time
    PCR
  • CE-IVD
    marked

Anyplex™ II
MTB/XDR Detection

Simultaneous detection of MTB and 13 mutations associated with XDR-TB

Anyplex™II MTB/XDR Detection simultaneously detects and identifies Mycobacterium tuberculosis (MTB) and 13 mutations associated with XDR-TB. Based on Seegene’s proprietary DPO™ and TOCE™ technologies, this assay performs on multiplex real-time PCR instruments and provide prompt diagnosis and appropriate treatment guideline for tuberculosis control.

Key Features and Benefits

  • Multiplex real-time PCR

    Simultaneous detection of Mycobacterium tuberculosis and 13 mutations associated with XDR-TB

  • Wild-type Control

    WTC[1](Wild-type Control) and Internal Control (IC) for assay validity

  • DNA extraction solution

    Reagent for DNA Detection is provided, purchase of DNA extraction kit is unnecessary

  • Wide range of specimens

    Wide range of applicable specimens

  • Automatic data analyzer

    Automated data interpretation and LIS interlocking with Seegene Viewer

  • Fast treatment decision

    Fast treatment decision by simultaneous screening and subtyping

  • Prediction of antibiotic resistance

    Detection and identification of mutations associated antibiotic resistance for appropriate infection control

  • Whole process validation

    Whole process validation from extraction to PCR by whole process control

  • Automatic data analyzer

    Automated data interpretation and LIS interlocking with Seegene Viewer

  • Analytes

    Anyplex™ II
    MTB/XDR Detection

    • Fluoroquinolone-resistance (7 mutations) [2]
    • Injectable drug-resistance (6 mutations) [2]
    • Mycobacterium tuberculosis (MTB)
    • Internal Control (IC)

  • Specimens

    • Sputum
    • Bronchial washing
    • Cultured cell
    • Fresh tissue

  • Ordering Information

    Product
    Cat No. / Size
    Anyplex™ II MTB/XDR Detection
    TB7302Y / 50 rxns

Result

These results indicate the detection of MTB infection in the FAM channel, and the Fluoroquinolone-resistance mutation in the HEX channel and the Injectable drug-resistance-R2* mutation in the Cal Red 610 channel.

(* High level Kanamycin, Amikacin, Capreomycin resistance)

Note

[1] The WTC is designed to be exhibited the same result pattern with drug-susceptible M. tuberculosis sample. The WTC reaction should be always performed in each testing run, and the drug-resistant result of unknown samples is analyzed on the basis of the result of WTC.

[2] Extensively Drug Resistance